Bioengineering: Diabetes, Cancer & Autoimmune Disease Breakthroughs
- the future of medicine may involve readily available replacement cells,tissues,and organs grown in labs,eliminating the need for donors.
- Currently, regenerative treatments often require broad immunosuppression, leaving patients vulnerable.
- Leonardo Ferreira, Ph.D.,a researcher at MUSC Hollings cancer Center,said that combining stem cell engineering with regulatory T cell (Treg) engineering is a step toward an accessible solution for...
Breakthroughs in bioengineering offer new hope! Researchers are pioneering innovative methods to combat Type 1 diabetes using beta cell transplants and localized immune protection. This cutting-edge approach, detailed in a recent study, combines stem cell and regulatory T cell engineering to create an accessible solution for those with diabetes. Explore how scientists are also targeting cancer and autoimmune diseases. News Directory 3 reports on the collaborative efforts at the Medical University of South Carolina and the University of Florida, which could revolutionize treatment. These advancements aim to replace reliance on organ donors, providing readily available replacement cells. Discover what’s next in this exciting field!
Stem Cell Therapy Offers New Hope for Type 1 Diabetes
Updated June 22,2025
the future of medicine may involve readily available replacement cells,tissues,and organs grown in labs,eliminating the need for donors. Though, regenerative medicine faces hurdles, notably directing stem cells to become specific cell types and preventing immune rejection.
Currently, regenerative treatments often require broad immunosuppression, leaving patients vulnerable. Researchers at the Medical University of South Carolina (MUSC) and the University of Florida are collaborating on a targeted approach to treat Type 1 diabetes (T1D). Their strategy involves transplanting tagged beta cells alongside specialized immune cells that provide localized immune protection.
Leonardo Ferreira, Ph.D.,a researcher at MUSC Hollings cancer Center,said that combining stem cell engineering with regulatory T cell (Treg) engineering is a step toward an accessible solution for T1D.
The collaboration, detailed in Cell reports, combines the beta cell engineering expertise of Holger russ’s lab at the University of Florida with surgical and chimeric antigen receptor (CAR) T cell expertise at Hollings.
T1D occurs when the immune system attacks pancreatic beta cells, which produce insulin. Patients must then manage blood glucose through constant monitoring and insulin administration to avoid complications. Islet cell transplantation, using donor beta cells, is an option for some, but it requires lifelong immunosuppression and depends on donor availability.
The researchers are exploring an alternative using tagged beta cells derived from stem cells. They are also using Tregs, immune cells that regulate immune responses, to induce localized immune protection.
“Most of the cells of the immune system are focused on killing invasive elements,” Ferreira said. “But Tregs are the generals of the immune system. They make sure that nothing goes overboard, and they train the immune system on how to respond in the future.”
In a mouse model, beta cells engineered from stem cells with an inactive epidermal growth factor receptor tag were transplanted into immunodeficient mice. The cells integrated and produced insulin. When exposed to aggressive immune cells, the transplanted beta cells were destroyed, mimicking what happens in T1D.
To prevent this, the researchers added specialized Tregs tagged with CAR technology to recognize the EGFR tag on the transplanted beta cells. This protected the beta cells, allowing them to remain functional.
Ferreira expressed enthusiasm about the results. “With this approach,” he said, “we made both the lock and the key for creating immune tolerance.”
What’s next
Ferreira and his team plan to expand their research, creating a library of differentiated stem cells and tagged protective Tregs for various applications, including cancer and autoimmune diseases like lupus. further research is needed to determine the optimal tag for human transplantation and the duration of Treg-mediated immune protection. The long-term effects of Treg treatment also require investigation to determine if repeated treatments are necessary. If triumphant, this approach could transform T1D management.